健择联合腹腔灌注顺铂治疗原发性肝细胞癌的临床研究

Research on gemcitabine combined cisplatin peritoneal perfusion in the treatment of primary hepatocellular carcinoma.

目的研究健择联合顺铂治疗原发性肝细胞癌的疗效,寻找合适的原发性肝细胞癌的化疗方案。方法分别选择健择联合腹腔灌注顺铂、吡柔比星联合腹腔灌注顺铂对原发性肝细胞癌进行化疗,比较治疗效果。结果健择联合腹腔顺铂实验组的有效率和临床获益率明显高于吡柔比星联合腹腔灌注顺铂对照组(P<0.05);实验组的生活质量评分明显优于对照组(P<0.05)。结论健择联合腹腔灌注顺铂对原发性肝细胞癌有明显的治疗效果。

Objective To study the effects of gemcitabine combined cisplatin peritoneal perfusion in the treatment of primary hepatocellular carcinoma, and look for the proper chemotherapeutic regimens. Methods The patients with primary hepatocellular carcinoma were treated with gemcitabine combined cisplatin peritoneal perfusion or pirarubicin combined cisplatin peritoneal perfusion individually, then, their curative effects were analyzed. Results The overall response rates and clinical profit rates in the patients group treated with gemcitabine combined cisplatin peritoneal perfusion were higer than it in the patients group treated with pirarubicin combined cisplatin peritoneal pedusion{ P 〈 0. 05 ） The quality of life score of experiment group was higher than it of control group （ P 〈 0. 05 ）. Conclusion The treatment of gemcitabine combined cisplatin peritoneal perfusion had curative effect on primary hepatocellular carcinoma.